Second quarter summary
Phase 1a/b study: positive placebo-controlled safety data for KL1333 and the first evidence of efficacy
Important events second quarter (Apr -
- Data from the Phase 1a/b clinical study of KL1333 was released and confirmed the safety and pharmacokinetic profile of the drug. In addition, in a cohort of eight patients (six dosed with KL1333, two with placebo), there were signs of efficacy across well-established relevant clinical endpoints including two patient-reported fatigue endpoints and a functional endpoint.
- Extraordinary General Meeting was held on
29 April 2021 . - The directed share issue, approved by the Extraordinary General Meeting, was completed. The Company raised approx.
SEK 76 million after deduction of issue costs. - Annual General Meeting was held on
20 May 2021 .
Important events after the reporting period
- The validation study of fatigue as an endpoint, for the KL1333 Phase 2/3 study, was completed.
Financial information
April-
- Net revenues:
SEK 18,000 (97,000) - Other operating income:
SEK 0,000 (34,000) - Loss before tax:
SEK 30,314,000 (20,312,000) - Loss per share:
SEK 0.08 (0.09) - Diluted loss per share:
SEK 0.08 (0.09)
January-
- Net revenues:
SEK 18,000 (105,000) - Other operating income:
SEK 0,000 (34,000) - Loss before tax:
SEK 51,770,000 (36,849,000) - Loss per share:
SEK 0.13 (0.18) - Diluted loss per share:
SEK 0.13 (0.18)
* APM Alternative perfomance measures, see definition on page 20.
The complete Interim report is available for download below and through the company's website www.abliva.com
© Modular Finance, source